ScRNA-seq data demonstrated that STING agonists DMXAA or cGAMP could greatly enhance the tumor control of CAR-T cells, and boost CAR-T cell trafficking and persistence with altered chemokine milieu [158]. This evidence concerns the gene STING1 and neoplasm.